These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 8878582)

  • 21. Inhibition of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductases by 2,4-diamino-5-[2-methoxy-5-(omega-carboxyalkyloxy)benzyl]pyrimidines: marked improvement in potency relative to trimethoprim and species selectivity relative to piritrexim.
    Rosowsky A; Forsch RA; Queener SF
    J Med Chem; 2002 Jan; 45(1):233-41. PubMed ID: 11754594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Triazine Inhibits Toxoplasma gondii tachyzoites in vitro and in vivo.
    Mui EJ; Jacobus D; Milhous WK; Schiehser G; Hsu H; Roberts CW; Kirisits MJ; McLeod R
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3463-7. PubMed ID: 16048961
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of a yeast assay for rapid screening of inhibitors of human-derived Pneumocystis carinii dihydrofolate reductase.
    Ma L; Jia Q; Kovacs JA
    Antimicrob Agents Chemother; 2002 Sep; 46(9):3101-3. PubMed ID: 12183283
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Altered trimethoprim-sulfamethoxazole ratios for prophylaxis and treatment of Toxoplasma gondii and Pneumocystis carinii dual infections in rat model.
    Brun-Pascaud M; Chau F; Garry L; Farinotti R; Derouin F; Girard PM
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Nov; 13(3):201-7. PubMed ID: 8898664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relative potency of 10 drugs with anti-Pneumocystis carinii activity in an animal model.
    Hughes WT; Killmar JT; Oz HS
    J Infect Dis; 1994 Oct; 170(4):906-11. PubMed ID: 7930735
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systemic Pneumocystis carinii pneumonia prophylaxis with dapsone and pyrimethamine fails to protect against extrapulmonary pneumocystosis.
    Carlin EM; Coker RJ; Goldin RD; Harris JR
    Genitourin Med; 1993 Apr; 69(2):130-2. PubMed ID: 8509094
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents.
    Gangjee A; Adair OO; Queener SF
    J Med Chem; 2003 Nov; 46(23):5074-82. PubMed ID: 14584957
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients.
    Opravil M; Hirschel B; Lazzarin A; Heald A; Pechère M; Rüttimann S; Iten A; von Overbeck J; Oertle D; Praz G
    Clin Infect Dis; 1995 Mar; 20(3):531-41. PubMed ID: 7756472
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro activity of epiroprim, a dihydrofolate reductase inhibitor, singly and in combination with brodimoprim and dapsone, against Mycobacterium leprae.
    Dhople AM
    Int J Antimicrob Agents; 1999 Aug; 12(4):319-23. PubMed ID: 10493608
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the activities of rifabutin combined with atovaquone or low-dose of cotrimoxazole for prevention of pneumocystosis and toxoplasmosis in a dual infection rat model.
    Brun-Pascaud M; Chau F; Rajagopalan-Levasseur P; Derouin F; Girard PM
    J Eukaryot Microbiol; 1996; 43(5):14S-15S. PubMed ID: 8822822
    [No Abstract]   [Full Text] [Related]  

  • 31. Anti-Toxoplasma effects of dapsone alone and combined with pyrimethamine.
    Derouin F; Piketty C; Chastang C; Chau F; Rouveix B; Pocidalo JJ
    Antimicrob Agents Chemother; 1991 Feb; 35(2):252-5. PubMed ID: 2024957
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dapsone in low doses prevents Pneumocystis carinii pneumonia in the rat model.
    González-Ruiz A; Haworth SJ; O'Neil AB; Warhurst DC
    J Infect; 1991 Mar; 22(2):143-52. PubMed ID: 2026888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Perspective on current and emerging drugs in the treatment of acute and chronic toxoplasmosis.
    Lapinskas PJ; Ben-Harari RR
    Postgrad Med; 2019 Nov; 131(8):589-596. PubMed ID: 31399001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of dihydrofolate reductase of Pneumocystis carinii and Toxoplasma gondii.
    Kovacs JA; Allegra CJ; Masur H
    Exp Parasitol; 1990 Jul; 71(1):60-8. PubMed ID: 2354716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis, and antifolate activity of new analogues of piritrexim and other diaminopyrimidine dihydrofolate reductase inhibitors with omega-carboxyalkoxy or omega-carboxy-1-alkynyl substitution in the side chain.
    Chan DC; Fu H; Forsch RA; Queener SF; Rosowsky A
    J Med Chem; 2005 Jun; 48(13):4420-31. PubMed ID: 15974594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 6,7-disubstituted 2,4-diaminopteridines: novel inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase.
    Jackson HC; Biggadike K; McKilligin E; Kinsman OS; Queener SF; Lane A; Smith JE
    Antimicrob Agents Chemother; 1996 Jun; 40(6):1371-5. PubMed ID: 8726003
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Conformationally restricted analogues of trimethoprim: 2,6-diamino-8-substituted purines as potential dihydrofolate reductase inhibitors from Pneumocystis carinii and Toxoplasma gondii.
    Gangjee A; Vasudevan A; Queener SF
    J Med Chem; 1997 Sep; 40(19):3032-9. PubMed ID: 9301665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activities of antifolate, antiviral, and other drugs in an immunosuppressed rat model of Pneumocystis carinii pneumonia.
    Walzer PD; Foy J; Steele P; Kim CK; White M; Klein RS; Otter BA; Allegra C
    Antimicrob Agents Chemother; 1992 Sep; 36(9):1935-42. PubMed ID: 1416884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis of 5-methyl-5-deaza nonclassical antifolates as inhibitors of dihydrofolate reductases and as potential antipneumocystis, antitoxoplasma, and antitumor agents.
    Gangjee A; Shi J; Queener SF; Barrows LR; Kisliuk RL
    J Med Chem; 1993 Oct; 36(22):3437-43. PubMed ID: 8230134
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A controlled trial of dapsone versus pyrimethamine-sulfadoxine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmosis in patients with AIDS.
    Payen MC; De Wit S; Sommereijns B; Clumeck N
    Biomed Pharmacother; 1997; 51(10):439-45. PubMed ID: 9863502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.